{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:40:18Z","timestamp":1780926018526,"version":"3.54.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clim.2026.110696","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:23:41Z","timestamp":1772583821000},"page":"110696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy and safety of telitacicept for myasthenia gravis in real-world practice and exploratory outcomes in the elderly subgroup"],"prefix":"10.1016","volume":"285","author":[{"given":"Xiang","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2026.110696_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1223322","article-title":"Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110696_bb0010","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clim.2026.110696_bb0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clim.2026.110696_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.clim.2026.110696_bb0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.clim.2026.110696_bb0030","article-title":"Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities","volume":"15","author":"Ma","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.clim.2026.110696_bb0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14737175.2023.2207739","article-title":"Conventional and emerging treatments and controversies in myasthenia gravis","volume":"23","author":"Evoli","year":"2023","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.clim.2026.110696_bb0040","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clim.2026.110696_bb0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14728214.2021.1952982","article-title":"Emerging drugs for the treatment of myasthenia gravis","volume":"26","author":"Menon","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.clim.2026.110696_bb0050","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment","volume":"31","author":"Gilhus","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clim.2026.110696_bb0055","article-title":"Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.clim.2026.110696_bb0060","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clim.2026.110696_bb0065","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"10.1016\/j.clim.2026.110696_bb0070","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clim.2026.110696_bb0075","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2026.110696_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116690","article-title":"Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study","volume":"411","author":"Litchman","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clim.2026.110696_bb0085","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","article-title":"Inebilizumab: First Approval","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.clim.2026.110696_bb0090","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1080\/1750743X.2025.2594349","article-title":"Evaluating inebilizumab in the treatment of generalized myasthenia gravis","volume":"17","author":"Carbunar","year":"2025","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clim.2026.110696_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103291","article-title":"Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases","volume":"148","author":"Zeng","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2026.110696_bb0100","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.clim.2026.110696_bb0105","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2026.110696_bb0110","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16322","article-title":"A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis","volume":"31","author":"Yin","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clim.2026.110696_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1270011","article-title":"Case report: Telitacicept in severe myasthenia gravis: a case study with multiple autoantibodies","volume":"14","author":"Guo","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110696_bb0120","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s00415-023-12036-y","article-title":"Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report","volume":"271","author":"Zhang","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2026.110696_bb0125","article-title":"Case report: a highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110696_bb0130","article-title":"Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review","volume":"16","author":"Song","year":"2025","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clim.2026.110696_bb0135","article-title":"Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110696_bb0140","article-title":"Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect","volume":"16","author":"Fang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110696_bb0145","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241251476","article-title":"Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study","volume":"17","author":"Lin","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clim.2026.110696_bb0150","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG-ADL in myasthenia gravis clinical research and care","volume":"65","author":"Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clim.2026.110696_bb0155","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3233\/JND-190464","article-title":"Retrospective analysis of eculizumab in patients with acetylcholine receptor antibody-negative myasthenia gravis: a case series","volume":"7","author":"Datta","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.clim.2026.110696_bb0160","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12883-022-02922-9","article-title":"Analysis of length of stay and treatment emergent complications in hospitalized myasthenia gravis patients with exacerbation","volume":"23","author":"Ramsaroop","year":"2023","journal-title":"BMC Neurol."},{"key":"10.1016\/j.clim.2026.110696_bb0165","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00415-026-13695-3","article-title":"Rapid efficacy of efgartigimod for generalized myasthenia gravis patients in acute exacerbations\/worsening: multicenter real-world retrospective study","volume":"273","author":"Lin","year":"2026","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2026.110696_bb0170","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241309793","article-title":"Short-term and long-term prognoses in AChR-ab positive very-late-onset myasthenia gravis patients","volume":"18","author":"Xie","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clim.2026.110696_bb0175","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1007\/s10072-024-07368-0","article-title":"Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients","volume":"45","author":"Di Stefano","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.clim.2026.110696_bb0180","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.nmd.2023.02.013","article-title":"Clinical characteristics and prognosis of very late-onset myasthenia gravis in China","volume":"33","author":"Tang","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.clim.2026.110696_bb0185","article-title":"Telitacicept as double-targeted therapy for myasthenia gravis coexisting with connective tissue disease: three case reports","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110696_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.843523","article-title":"Efficacy and safety of tacrolimus therapy for a single Chinese cohort with very-late-onset myasthenia gravis","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clim.2026.110696_bb0195","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.2147\/JIR.S423098","article-title":"A pilot study on tocilizumab in very-late-onset myasthenia gravis","volume":"16","author":"Yang","year":"2023","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.clim.2026.110696_bb0200","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40262-014-0175-9","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis","volume":"53","author":"Chen","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.clim.2026.110696_bb0205","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/cpdd.1136","article-title":"Pharmacokinetic characteristics, safety, and tolerability of telitacicept, an injectable recombinant human B-lymphocyte stimulating factor receptor-antibody fusion protein, in healthy Chinese subjects","volume":"11","author":"Xie","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.clim.2026.110696_bb0210","article-title":"B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept","volume":"5","author":"Ji","year":"2024","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.clim.2026.110696_bb0215","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00415-025-13563-6","article-title":"A pilot study of telitacicept in predominantly immune-mediated necrotizing myopathy, retrospective analysis of a monocentric Chinese cohort","volume":"273","author":"Xiang","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2026.110696_bb0220","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.2147\/DDDT.S493923","article-title":"The latest Progress in the application of Telitacicept in autoimmune diseases","volume":"18","author":"Liu","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.clim.2026.110696_bb0225","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10067-013-2176-8","article-title":"NK cells dysfunction in systemic lupus erythematosus: relation to disease activity","volume":"32","author":"Henriques","year":"2013","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.clim.2026.110696_bb0230","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1189\/jlb.4RU0315-081RR","article-title":"Recent findings on the role of natural killer cells in the pathogenesis of systemic lupus erythematosus","volume":"98","author":"Spada","year":"2015","journal-title":"J. Leukoc. Biol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626000343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626000343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:37:58Z","timestamp":1779190678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661626000343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":46,"alternative-id":["S1521661626000343"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110696","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of telitacicept for myasthenia gravis in real-world practice and exploratory outcomes in the elderly subgroup","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110696"}}